1670.9000 12.40 (0.75%)
NSE Oct 10, 2025 15:51 PM
Volume: 1.5M
 

Prabhudas Lilladhar
Several observations related to lapses in injectable formulation SUNP's Halol (Baroda) facility underwent a routine cGMP(Current Good Manufacturing Practice) audit by USFDA during 3rd-13th December, and the inspection concluded with 8 observations in Form-483.We believe that few observations are critical in nature and there is likely possibility of conversion into WL post 90 days. The observations indicated lack of authenticity of data pertaining to microbiology tests, contaminations, and...
Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended